

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A pharmaceutical composition comprising an alpha-adrenoceptor antagonist, a 5-HT₄-receptor antagonist and a pharmaceutically acceptable carrier.
2. (Original) A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is non-selective.
3. (Original) A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is selective for the alphas-receptor.
4. (Original) A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is selected from abanoquil, alfuzosin, indoramin, tamsulosin, doxazosin, parvosin, terazosin, abanoquil, prazosin and pharmaceutically acceptable salts thereof.
5. (Previously Presented) A pharmaceutical compositions as claimed in claim 1 wherein the 5-HT₄-receptor antagonist is selective for the 5-HT₄-receptor.
6. (Previously Presented) A pharmaceutical composition as claimed in claim 1 wherein the 5-HT₄-receptor antagonist is selected from SB 205800, SB 203186, R50595, GR 113808, GR 125487, GR 138897, LY-353433, DAU 6285, SDZ 205-557, RS 23597-190, or (3S-trans)-4-(4-[[(8-chloro-3,4-dihydro-2H benzo[b] [1,4]dioxepine-6-carbonyl)-amino]-methyl]-3-hydroxy-piperidin- 1-yl)-butyric acid and pharmaceutically acceptable salts thereof.
7. (Original) A pharmaceutical composition as claimed in claim 6 wherein the 5-HT₄-receptor antagonist is (3S-trans)-4-(4-[[(8-chloro-3,4-dihydro-2H-benzo[b]

[1,4]dioxepine-6-carbonyl)-amino]-methyl]-3-hydroxy-piperidin-1-yl)-butyric acid and pharmaceutically acceptable salts thereof.

8. – 11. (Canceled)

12. (Currently Amended) A product comprising a first pharmaceutically acceptable composition containing an alpha-adrenoceptor antagonist and a second pharmaceutically acceptable composition containing a 5-HT₄-receptor antagonist for use as a combined preparation for simultaneous or sequential use in treating the lower urinary tract symptoms associated with overactive bladder or benign prostatic hyperplasia in mammals.

13. (Previously Presented) A method for treating lower urinary tract symptoms comprising administering to a host in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist.

14. (Previously Presented) A method for treating lower urinary tract symptoms associated with overactive bladder comprising administering to a host in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist.

15. (Previously Presented) A method for treating the lower urinary tract symptoms associated with mild to moderate benign prostrate hyperplasia in mammals comprising administering to a mammal in need thereof an effective amount of an alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist.